📊 CALC Key Takeaways
Investment Thesis
CalciMedica is a pre-revenue/early-stage biotech company with severe financial distress, evidenced by negative stockholders' equity of -$6.6M and liabilities exceeding assets by $6.6M. The company is burning cash at an unsustainable rate with -$21.2M operating cash flow against only $11.5M in cash reserves, projecting less than 6 months of runway at current burn rates. Without significant financing, clinical progress, or a clear path to profitability, the equity faces substantial dilution risk or potential insolvency.
CALC Strengths
- Maintains positive current ratio of 3.58x relative to current liabilities
- Holds $11.5M in cash equivalents providing near-term operational flexibility
- Operating in pharmaceutical sector with potential for high-value therapeutic breakthroughs
CALC Risks
- Negative stockholders' equity of -$6.6M indicates liabilities exceed assets; equity holders in subordinate position
- Operating cash burn of -$21.2M annually with only $11.5M cash runway (~6 months at current rate)
- Revenue collapse of -29.7% YoY with minimal revenue generation ($713K) indicates failed commercialization or delayed clinical progress
- Operating margin of -3242.8% demonstrates pre-commercial stage with no path to profitability visible in near term
- No insider buying activity in last 90 days suggests lack of management confidence
- Dependency on external financing creates severe dilution risk for existing shareholders
Key Metrics to Watch
- Cash runway and next financing timeline
- Clinical trial progression and regulatory milestones
- Quarterly cash burn rate and operating cash flow trends
- Revenue growth trajectory and commercial product launches
- Debt restructuring or capital raise announcements
CALC Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.58x current ratio provides a solid financial cushion.
CALC Profitability Ratios
CALC vs Healthcare Sector
How CalciMedica, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CALC Balance Sheet & Liquidity
CALC 5-Year Financial Trend
5-Year Trend Summary: CalciMedica, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.22 indicates the company is currently unprofitable.
CALC Growth Metrics (YoY)
CALC Capital Allocation
CALC SEC Filings
Access official SEC EDGAR filings for CalciMedica, Inc. (CIK: 0001534133)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CALC
What is the AI rating for CALC?
CalciMedica, Inc. (CALC) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CALC's key strengths?
Maintains positive current ratio of 3.58x relative to current liabilities. Holds $11.5M in cash equivalents providing near-term operational flexibility.
What are the risks of investing in CALC?
Negative stockholders' equity of -$6.6M indicates liabilities exceed assets; equity holders in subordinate position. Operating cash burn of -$21.2M annually with only $11.5M cash runway (~6 months at current rate).
What is CALC's revenue and growth?
CalciMedica, Inc. reported revenue of $713.0K.
Does CALC pay dividends?
CalciMedica, Inc. does not currently pay dividends.
Where can I find CALC SEC filings?
Official SEC filings for CalciMedica, Inc. (CIK: 0001534133) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CALC's EPS?
CalciMedica, Inc. has a diluted EPS of $-1.97.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.